Gubra ApS

https://www.gubra.dk

Founded in 2008, Gubra is a privately held biotech company located in Denmark delivering scientific counselling, contract research services and discovery programmes. For target and drug discovery programmes Gubra leverages its proprietary machine-learnings powered streaMLine platform. Gubra’s preclinical focus areas are obesity, NASH, diabetes, kidney diseases, cardiovascular disease, CNS diseases, lung diseases and are continuously expanding. Gubra experts cover a number of preclinical disciplines, including in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS, computational biology, and ex vivo assays. Gubra has a hybrid business model with a pipeline of early target and drug discovery programs aimed for partnering while also delivering preclinical services to customers by combining cutting-edge technology with our accumulated experience and proven methodology. *

	Start	2008-01-01 established
	Industry	BIOTECH
	Industry 2	obesity drug
	Person	Blou, Henrik (Gubra ApS 201709 CEO before EpiTherapeutics ApS 201304 Business Development Director)

	Region	Hørsholm
	Country	Denmark
	Street	11B Hørsholm Kongevej
	City	2970 Hørsholm
	Tel	+45-3152 2650
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2022-12-31)
	Currency	DKK
	Annual sales	199,381,000 (revenue, annual, consolidated (2022) 2022-12-31)
	Profit	4,310,000 (2022-12-31)
	Cash	71,925,000 (2022-12-31)

		* Document for »About Section«: Gubra ApS. (2/10/22). "Press Release: Gubra ApS and Silence Therapeutics plc Collaborate to Develop RNAi Therapies against Novel Liver-directed Targets from Gubra’s streaMLine Platform". Hørsholm.

		Record changed: 2024-02-12